Up to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported a way to track changes with whole-tissue biospy phenotyping.
NuCana raises US$114m in IPO of ADSs
Latest NewsScotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair.
Researchers unravel patterns of cancer heterogeneity
Latest NewsUp to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported a way to track changes with whole-tissue biospy phenotyping.
Talents: HR Flash
OpinionThe European Biotech market is extremely dynamic, acknowledged as being number two in the world of market rankings. This is a cause for celebration!
Ablynx takes Phase III hurdle in acquired TTP
Latest NewsBelgian nanobody developer Ablynx NV‘s nanobody caplacizumab has met relevant endpoints in the pivotal Hercules Phase III study in patients with thrombotic thrombocytopenic purpura (aTTP), paving the way to market authorisation in Europe and the US.
MD8 Airscan®
ProductsActive sampling of airborne viruses, bacteria, yeasts and fungi.
Jesper Ericsson named new Chief Executive Officer by Symcell Sverige AB
AppointmentsSymcel announced that Jesper Ericsson has joined Symcel as Chief Executive Officer.
Dipstick test detects Zika
Latest NewsA newly-developed, fast, and cost-effective dipstick test sensitively and specifically identified Zika virus and all four dengue virus subtypes without any detectable cross-reactivity.
Why to watch out Spain
Latest NewsEvotec acquires stake in Exscientia
Latest NewsGerman CRO Evotec AG announced an €15m investment in British Exscienta Ltd. to push artificial intelligence (AI)-driven drug discovery.
Genmab bags €25m milestone upon market approval of daratumumab
Latest NewsDanish Genmab A/S has received market approval in Japan for its anti-CD38 antibody daratumumab (DARZALEX®) as therapy for relapsed or refractory Multiple Myeloma.